ProKidney jumps on positive mid-stage data for kidney disease drug

Prokidney

08/07/2025 13:12

** Shares of ProKidney PROK.O rise 62.4% to $1.25 cents premarket

** Co says its drug, rilparencel, showed improvement in kidney function decline in patients with chronic kidney disease and diabetes during mid-stage trial

** PROK has upcoming meeting with Food and Drug Administration to confirm approach of drug's planned late-stage trial

** Up to last close, stock down 64% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))